{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"80"}],"units":"Participants"}],"title":"At Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"}],"units":"Participants"}],"title":"At Disease Progression or Relapse"}],"denoms":[{"counts":[{"groupId":"OG000","value":"106"}],"units":"Participants"}],"description":"A BCR-ABL mutation is defined as the presence of a detectable amino acid substitution in the ABL kinase domain, assessed by Real-time quantitative PCR.","groups":[{"description":"Children and adolescents newly diagnosed with Philadelphia chromosome positive acute lymphocytic leukemia (Ph+ ALL) treated with standard multiagent chemotherapy and Dasatinib (either in tablets or Powder For Oral Suspension (PFOS)) at a dose of 60 mg/m2 daily.","id":"OG000","title":"Dasatinib Cohort"}],"paramType":"NUMBER","populationDescription":"All treated participants with available measurements","reportingStatus":"POSTED","timeFrame":"At baseline (prior to start of study treatment) and at disease progression or relapse (up to approximately 3 years)","title":"Percentage of Participants With BCR-ABL Mutations at Baseline and at Time of Disease Progression or Relapse","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}